Vor Bio to Participate in the Stifel 2024 Healthcare Conference
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host 1x1 investor meetings at the Stifel 2024 Healthcare Conference.
馬薩諸塞州劍橋，2024年11月12日（GLOBE NEWSWIRE）——臨床階段的細胞和基因組工程公司Vor Bio（納斯達克股票代碼：VOR）今天宣佈，它將在Stifel 2024醫療保健會議上參加爐邊談話並主辦1x1投資者會議。
Stifel 2024 Healthcare Conference
Fireside Chat: Monday, November 18, 2024 at 2:25 pm ET
Location: New York, NY
Stifel 2024 年醫療保健會議
爐邊談話：美國東部時間 2024 年 11 月 18 日星期一下午 2:25
地點：紐約州紐約
A live webcast and archived replay of the fireside chat will be available on the investors section of .
的投資者專區將提供爐邊談話的網絡直播和存檔重播。
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: .
關於 Vor Bio
Vor Bio是一家臨床階段的細胞和基因組工程公司，旨在通過設計造血幹細胞來實現移植後的靶向治療，從而改變血液癌患者的護理標準。欲了解更多信息，請訪問：。
Contact:
聯繫人：
Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com
媒體與投資者
莎拉·斯賓塞
+1 857-242-6076
sspencer@vorbio.com
